ANGX vs JAZZ · rev $321.6M vs P/E 1988, rev $2.28B
Angel Studios, Inc. (ANGX) versus Jazz Pharmaceuticals PLC (JAZZ) — a side-by-side from cached financials, not a winner call.
Angel Studios, Inc. (ANGX) is a entertainment company listed on NYSE.
Jazz Pharmaceuticals PLC (JAZZ) is a biotechnology company listed on US.
Latest reported ANGX revenue for 2025-12-31 was $321.6M. Net income was -$170.5M. Revenue was up 233.2% from 2024-12-31 to 2025-12-31. ANGX currently screens at market cap $599.3M.
Latest reported JAZZ revenue for 2026-06-30 was $2.28B. Net income was $485.9M. JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1.
ANGX currently screens at market cap $599.3M. JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1.
Not investment advice. Open the ANGX and JAZZ stock pages for the full models.
Not investment advice.